We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Highly Accurate Universal Diagnostic Blood Test Detects Alzheimer's Disease and Mild Cognitive Impairment

By LabMedica International staff writers
Posted on 20 Feb 2024
Print article
Image: The new blood test could be a game-changer for the diagnosis and precision treatment of Alzheimer\'s Disease (Photo courtesy of Shutterstock)
Image: The new blood test could be a game-changer for the diagnosis and precision treatment of Alzheimer\'s Disease (Photo courtesy of Shutterstock)

Alzheimer's disease (AD) currently affects over 50 million people globally. A key characteristic of AD is the build-up of harmful amyloid beta (Aβ) in the brain, which impairs and destroys brain cells. This results in progressive memory loss, cognitive decline, and difficulties with everyday tasks and communication. The recent authorization of the AD medication Lecanemab, which targets mild cognitive impairment (MCI) or mild AD-related dementia with high Aβ levels in the brain, provides new hope. However, most individuals with these conditions remain undiagnosed and untreated. This is largely due to the difficulties in early diagnosis, as increased Aβ levels are typically only measurable through expensive brain imaging or invasive procedures. Additionally, diagnosis is largely based on clinical observation of symptoms that appear 10-20 years after the onset of the disease. By this stage, the disease is often advanced and challenging to treat. Now, a breakthrough has been made with the development of a simple blood test that can accurately identify individuals with MCI and mild AD, as well as detect increased Aβ in the brain, offering a transformative approach to AD diagnosis and treatment.

An international team led by the Hong Kong University of Science and Technology (HKUST, Hong Kong) has developed an innovative blood test that can detect AD and MCI early with remarkable accuracy rates of over 96% and 87%, respectively. This test is effective across different ethnic groups, providing a universal solution for diagnosing and managing AD. In a multinational study with participants from Chinese and European backgrounds, the research team confirmed the test's effectiveness in distinguishing individuals with AD and MCI from those without cognitive impairments, as well as its ability to detect brain amyloid pathology. The findings underscore the test’s potential for broad application across various ethnic and regional groups.

Unlike current blood tests that typically focus on a single biomarker to indicate brain pathology, this new test measures levels of 21 proteins simultaneously. This approach reveals alterations in multiple critical biological pathways, leading to more precise classification of AD and MCI, and better monitoring of disease progression. By providing a comprehensive AD profile for each individual, this test paves the way for personalized treatment strategies, known as precision medicine, potentially revolutionizing AD diagnosis and management.

"Our blood test heralds a new era of simple, effective, and less invasive diagnostics, and by expanding the scope of our research to include diverse populations, we have taken a crucial step towards making our test a universally applicable tool for AD diagnosis," said Prof. Nancy IP from HKUST who led the team. "Our test can also be used to screen suitable individuals for specific drug treatments in clinical studies, and closely monitor disease progression and drug responses. In the future, it may also facilitate the development of personalized treatments, by shedding light on the molecular underpinnings of AD that vary from person to person and between ethnicities."

Related Links:

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.